{"id":"NCT03285490","sponsor":"Almirall, S.A.","briefTitle":"A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)","officialTitle":"A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-15","primaryCompletion":"2018-05-07","completion":"2019-04-24","firstPosted":"2017-09-18","resultsPosted":"2021-03-10","lastUpdate":"2021-03-10"},"enrollment":351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"KX2-391 Ointment 1%","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"KX2-391 Ointment 1%","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.","primaryOutcome":{"measure":"Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions","timeFrame":"Day 57","effectByArm":[{"arm":"Placebo","deltaMin":13,"sd":null},{"arm":"KX2-391 Ointment 1%","deltaMin":54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["33567191"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":173},"commonTop":["Application site pruritus","Application site pain","Upper respiratory tract infection","Viral upper respiratory tract infection","Skin abrasion"]}}